Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 4/20 | 0.62 |
| ▸ | CDC25A | P30304 | 1/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21246049 | 0.88 | ICMT (0.61) | ICMTCDC25ACNR1CNR2MCL1 | |
| SCHEMBL8416334 | 0.88 | CDC25A (0.65) | ICMTCDC25ACREBBPL3MBTL1CNR1 | |
| SCHEMBL28840780 | 0.87 | CREBBP (0.62) | ICMTCDC25ACREBBPL3MBTL1CNR1 | |
| SCHEMBL9038902 | 0.86 | CDC25A (0.56) | ICMTCDC25ACREBBPL3MBTL1CNR1 | |
| SCHEMBL21245248 | 0.84 | CDC25A (0.56) | ICMTCDC25ACREBBPL3MBTL1CNR1 | |
| SCHEMBL16259057 | 0.82 | ICMT (0.61) | ICMTCDC25ACNR2 | |
| SCHEMBL14333614 | 0.82 | CNR1 (0.68) | CREBBPCNR1CNR2LMNA | |
| SCHEMBL18171795 | 0.81 | ALDH1A1 (0.66) | CREBBPL3MBTL1LMNAALOX5 | |
| SCHEMBL17102877 | 0.80 | CDC25A (0.75) | ICMTCDC25ACNR1CNR2 | |
| SCHEMBL15747719 | 0.80 | CDC25A (0.75) | ICMTCDC25ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV INDIANA TRUSTEES (US) | 2023-04-20 | — | — | US | disclosed |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210070784-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-03-11 | — | — | US | disclosed |
| WO-2019153007-A2 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE BOARO OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070784-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | NAMPT, NNT, NAPRT | ICMT 387/4885CDC25A 3597/4885CREBBP 833/4885 |
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | NAMPT, NNT, NAPRT | ICMT 387/4885CDC25A 3597/4885CREBBP 833/4885 |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | NAMPT, NNT, NAPRT | ICMT 387/4885CDC25A 3597/4885CREBBP 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.